References of "DELANAYE, Pierre"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEnzymatic creatinine assays allowestimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation
Kuster, Nils; Cristol, Jean-Paul; CAVALIER, Etienne ULiege et al

in Clinica Chimica Acta (2014), 428

The National Kidney Disease Education Program group demonstrated that MDRD equation is sensitive to creatinine measurement error, particularly at higher glomerular filtration rates. Thus, MDRD-based eGFR ... [more ▼]

The National Kidney Disease Education Program group demonstrated that MDRD equation is sensitive to creatinine measurement error, particularly at higher glomerular filtration rates. Thus, MDRD-based eGFR above 60 mL/min/1.73 m2 should not be reported numerically. However, little is known about the impact of analytical error on CKD-EPI-based estimates. This study aimed at assessing the impact of analytical characteristics (bias and imprecision) of 12 enzymatic and 4 compensated Jaffe previously characterized creatinine assays on MDRD and CKD-EPI eGFR. In a simulation study, the impact of analytical error was assessed on a hospital population of 24 084 patients. Ability using each assay to correctly classify patients according to chronic kidney disease (CKD) stages was evaluated. For eGFR between 60 and 90 mL/min/1.73 m2, both equations were sensitive to analytical error. Compensated Jaffe assays displayed high bias in this range and led to poorer sensitivity/specificity for classification according to CKD stages than enzymatic assays. As compared to MDRD equation, CKD-EPI equation decreases impact of analytical error in creatinine measurement above 90 mL/min/1.73 m2. Compensated Jaffe creatinine assays lead to important errors in eGFR and should be avoided. Accurate enzymatic assays allow estimation of eGFR until 90 mL/min/1.73 m2 with MDRD and 120 mL/min/1.73 m2 with CKD-EPI equation. [less ▲]

Detailed reference viewed: 31 (1 ULiège)
Full Text
Peer Reviewed
See detailCockcroft&Gault and CKD-EPI equations: are these equations concordant to adjust drug dosage?
BOUQUEGNEAU, Antoine ULiege; Vidal-Petito, E; Vrtovsnik, F et al

Poster (2014)

Detailed reference viewed: 14 (3 ULiège)
Full Text
Peer Reviewed
See detailAccuracy of Cockcroft&Gault and CKD-EPI equations to estimate glomerular filtration rate in obese population
BOUQUEGNEAU, Antoine ULiege; Vidal-Petiot, E; Vrtovsnik, F et al

Poster (2014)

Detailed reference viewed: 8 (2 ULiège)
Peer Reviewed
See detailAssessing kidney function
DELANAYE, Pierre ULiege; Rule, AD

in Kimmel, PL; Rosenberg, ME (Eds.) Chronic Renal Disease (2014)

Detailed reference viewed: 7 (2 ULiège)
See detailPeut-on approcher l’ostéoporose de l’insuffisant rénal chronique par les biomarqueurs ?
DELANAYE, Pierre ULiege

Conference given outside the academic context (2014)

Detailed reference viewed: 7 (0 ULiège)
See detailEvaluation de la fonction rénale
DELANAYE, Pierre ULiege

Conference given outside the academic context (2014)

Detailed reference viewed: 3 (0 ULiège)
See detailNephrology and Clinical Chemistry: the essential link
DELANAYE, Pierre ULiege

Scientific conference (2014)

Detailed reference viewed: 20 (0 ULiège)
See detailEstimation du DFG en 2014 : le CKD-EPI (en autres choses…)
DELANAYE, Pierre ULiege

Conference (2014)

Detailed reference viewed: 3 (1 ULiège)
Full Text
Peer Reviewed
See detailCreatinine-based GFR estimating equations in kidney transplant recipients
DELANAYE, Pierre ULiege

in American Journal of Kidney Diseases (2014), 64(5), 818

Detailed reference viewed: 28 (2 ULiège)
Full Text
See detailL'Estimation de la filtration glomérulaire en 2014: Intérêts et limites des tests et formules
Hougardy, Jean-Michel; DELANAYE, Pierre ULiege; Le Moine, Alain et al

in Revue Médicale de Bruxelles (2014), 35(4), 250-257

Detailed reference viewed: 57 (0 ULiège)
Full Text
Peer Reviewed
See detailClinical and biological determinants of sclerostin plasma concentration in hemodialysis patients
DELANAYE, Pierre ULiege; KRZESINSKI, Jean-Marie ULiege; Warling, Xavier et al

in Nephron. Clinical Practice (2014), 128

Background: Sclerostin is a potent inhibitor of bone formation, but the meaning of its serum levels remains undetermined. We evaluated the association between sclerostin levels and clinical or biological ... [more ▼]

Background: Sclerostin is a potent inhibitor of bone formation, but the meaning of its serum levels remains undetermined. We evaluated the association between sclerostin levels and clinical or biological data in hemodialyzed patients (HD), notably parathormone (PTH), biomarkers of bone turnover, vascular calcifications and mortality after 2 years. Methods: 164 HD patients were included in this observational study. The calcification score was assessed with the Kauppila method. Patients were followed for 2 years. Results: Median sclerostin levels were significantly (p < 0.0001) higher in HD versus healthy subjects (n = 94) (1,375 vs. 565 pg/ml, respectively). In univariate analysis a significant association (p < 0.05) was found between sclerostin and age, height, dialysis vintage, albumin, troponin, homocysteine, PTH, C-terminal telopeptide of collagen type I, bone-specific alkaline phosphatase and osteoprotegerin, but not with the calcification score. In a multivariate model, the association remained with age, height, dialysis vintage, troponin, homocysteine, phosphate, PTH, but also with vascular calcifications. Association was positive for all variables, except PTH and vascular calcifications. The baseline sclerostin concentration was not different in survivors and non-survivors. Conclusions: We confirm a higher concentration of sclerostin in HD patients, a positive association with age and a negative association with PTH. A positive association with phosphate, homocysteine and troponin calls for additional research. The clinical interest of sclerostin to assess vascular calcifications in HD is limited and no association was found between sclerostin and mortality. [less ▲]

Detailed reference viewed: 45 (22 ULiège)